Entries |
Document | Title | Date |
20100273719 | USE OF SOMATOSTATIN ANALOGS IN MENINGIOMA - The present invention relates to the use of a Somatostatin (SRIF) analog which has a high binding affinity to human SSTR1,2,3,5, or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for the treatment of meningioma. | 10-28-2010 |
20100323970 | SAP VARIANTS AND THEIR USE - Polypeptides are susceptible to denaturation or enzymatic degradation in the blood, liver or kidney. Due to the low stability of some polypeptides, it has been required to administer polypeptide drugs in a sustained frequency to a subject in order to maintain an effective plasma concentration of the active substance. Furthermore, pharmaceutical compositions of therapeutic peptides preferably have a shelf-life of several years in order to be suitable for common use. However, peptide compositions are inherently unstable due to sensitivity towards chemical and physical degradation. In part, the invention provides SAP variant proteins, compositions, pharmaceutical preparations and formulations having a prolonged in vivo half-life, prolonged shelf-life, or rather increased in vitro stability, or increased manufacturing efficiency compared to human SAP. Advantages of increased plasma half-life include, but are not limited to, reducing the amount and/or frequency of dosing. | 12-23-2010 |
20110009334 | SYSTEM AND METHOD FOR INHIBITING CELLULAR PROLIFERATION WITH TACHYKININS - Systems and methods are described providing therapeutic preparations of tachykinins, and more specifically sialokinins, for treating various types of abnormal cellular proliferation conditions in regions of tissue associated with the body of a patient. The sialokinins may be isolated and purified from natural or bioengineered sources, or may be synthesized, and may be combined into, with, or on an implant for local elution or otherwise as a powder mixed in a carrier vehicle for injection delivery. Tumors, warts, and restenosis are abnormal cellular proliferation conditions treated by therapeutic doses of sialokinin. Size of the tissue structure to be treated is used to determine the therapeutic dose of sialokinin. The sialokinins are either locally or systemically delivered at therapeutic doses for the desired effect. Implants such as stents are coated with sialokinins for local elution at the site of injury or tissue otherwise vulnerable to harmful conditions treated by the sialokinin. | 01-13-2011 |
20110034397 | INTESTINAL IMMUNE SYSTEM STIMULATOR - Disclosed is an agent, γ-glutamylcysteine, which can effectively and safely stimulate the intestinal immune system. γ-Glutamylcysteine can be formulated in a pharmaceutical composition, a food, and/or a beverage, and used for the treatment or prevention of infectious diseases, diarrhea, polyps, tumors, enteritis or allergy. | 02-10-2011 |
20110039787 | COMPOSITIONS, KITS AND METHODS FOR TREATING BENIGN PROSTATE HYPERPLASIA - The present disclosure is directed to compositions and kits comprising degarelix or a pharmaceutically acceptable salt thereof for the treatment of benign prostate hyperplasia (BPH), methods for treating BPH, and methods for preparing compositions of degarelix or a pharmaceutically acceptable salt thereof. | 02-17-2011 |
20110098232 | Methods For The Selective Treatment Of Tumors By Calcium-Mediated Induction Of Apoptosis - Available evidence indicates that tumor cells exhibit consistent abnormalities in Calcium influx and intracellular storage of sequestered Calcium when compared to normal cells. The present invention provides clinical methods by which such differences are exploited to induce Apoptosis selectively in tumor cells while sparing normal cells. These methods are based upon employing drugs that, acting alone or in synergistic combinations, produce an increase in intracellular Calcium loading such that either or both of two major Apoptotic pathways are triggered to produce selective killing of malignant cells. Since the invention is based upon fundamental cell cycle requirements, to the extent that Calcium handling abnormalities are a general characteristic of the malignant state, the methods presented here are widely applicable regardless of tissue of origin and degree of cellular de-differentiation. | 04-28-2011 |
20110218154 | HISTONE DEACETYLASES, AND USES RELATED THERETO - The present invention concerns the discovery that proteins encoded by a family of genes, termed here HDx-related genes, which are involved in the control of chromatin structure and, thus in transcription and translation. The present invention makes available compositions and methods that can be utilized, for example to control cell proliferation and differentiation in vitro and in vivo. | 09-08-2011 |
20120015887 | SYNTHETIC PEPTIDE AND USES THEREOF - A 4-copy branched peptide represented by a formula of (X | 01-19-2012 |
20120028907 | METHODS FOR IDENTIFICATION OF TUMOR PHENOTYPE AND TREATMENT - The disclosure relates to methods for identifying a tumor as an E2F-responsive gene over-expressing (ERGO) tumor, methods of determining the likelihood that an ERGO tumor patient will survive to a future date, methods of treating an ERGO tumor in a patient, and methods of selecting patients diagnosed as ERGO tumor prostate cancer patients for aggressive clinical treatment. The methods of the disclosure are applicable to ERGO tumors present in different human organs and tissues such as breast, lung, thyroid, ovary, and prostate. | 02-02-2012 |
20120028908 | Methods of Manufacturing Crystalline Forms of Rapamycin Analogs - A process for preparing a crystalline rapamycin analog includes: combining the rapamycin analog with an organic medium to form a mixture; incubating the mixture until the rapamycin analog crystallizes; and recovering the crystalline rapamycin analog. The organic medium can be a solvent, and the process can include causing the rapamycin analog to dissolve into the solvent, and incubating the solvent until the rapamycin analog crystallizes. The following can also be performed: forming a slurry of crystalline rapamycin analog; stirring the rapamycin analog mixture until the rapamycin analog crystallizes; saturating the rapamycin analog solution; forming a supersaturated rapamycin analog solution; combining an antisolvent with the rapamycin analog and the solvent to form a biphasic mixture, and incubating the biphasic mixture to cause a liquid-liquid phase split. | 02-02-2012 |
20120101044 | GOLD (III) COMPLEXES WITH OLIGOPEPTIDES FUNCTIONALIZED WITH SULFUR DONORS AND USE THEREOF AS ANTITUMOR AGENTS - The invention concerns Au(III) complexes of the type [Au | 04-26-2012 |
20120108520 | Antimicrobial Compounds and Formulations - The invention relates to the use of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto at least two bulky and lipophilic groups and having at least one more cationic than anionic moiety, in the manufacture of a medicament for destabilising microbial cell membranes and the use as a membrane acting antimicrobial agent of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto a super bulky and lipophilic group comprising at least 9 non-hydrogen atoms and having at least two more cationic than anionic moieties and to methods of treatment involving such molecules, in particular peptides including peptide derivatives, and peptidomimetics. | 05-03-2012 |
20120172311 | PEPTIDOMIMETIC MACROCYCLES - The present invention provides biologically active crosslinked polypeptides with improved properties relative to their corresponding precursor polypeptides, having good cell penetration properties and reduced binding to human proteins. The invention additionally provides methods of identifying and making such improved polypeptides. | 07-05-2012 |
20120202749 | SECRETED FRIZZLED RELATED PROTEIN, SFRP, FRAGMENTS AND METHODS OF USE THEREOF - The invention stems from the discovery that sFRP and fragments thereof can bind to members of the Wnt family of proteins and cause an increase in Wnt biological activity. Furthermore, fragments of sFRP that do not contain the CRD domain are shown to bind to Wnt proteins and modulate Wnt biological activity. Accordingly, the invention provides these sFRP fragments and variants of these fragments, as well as vectors and host cells containing nucleic acid sequences encoding the sFRP fragments and variants. | 08-09-2012 |
20120208768 | SPECIFIC BINDING SITES IN COLLAGEN FOR INTEGRINS AND USE THEREOF - The present invention identified a high affinity binding sequence in collagen type III for the collagen-binding integrin I domains. Provided herein are the methods used to characterize the sequence, the peptides comprising this novel sequence and the use of the peptides in enabling cell adhesion. Also provided herein are methods to identify specific integrin inhibitors, sequences of these inhibitors and their use in inhibiting pathophysiological conditions that may arise due to integrin-collagen interaction. | 08-16-2012 |
20130040893 | TREATMENT OF PROLIFERATIVE DISORDERS - Inhibitors of cIAP-1 and methods and compositions for treating proliferative disorders. | 02-14-2013 |
20130130990 | USE OF SPINK6 GENE AND ITS ENCODED PROTEIN FOR THE PREPARATION OF AN ANTI-TUMOR DRUG - The present invention describes use of spink6 gene and the encoded protein in the manufacture of an anti-tumor drug. spink6 gene has a nucleotide sequence designated as SEQ ID NO:1, and the protein encoded by spink6 gene has an amino acid sequence designated as SEQ ID NO:2. The protein encoded by spink6 gene and its derivatives can be used as potential drugs for treatment of human diseases caused by dysregulation of the cell cycle control, such as various malignant tumors, cell abnormal proliferation, and the like. | 05-23-2013 |
20130157958 | DIAGNOSIS OF COWDEN AND COWDEN-LIKE SYNDROME BY DETECTION OF DECREASED KILLIN EXPRESSION - A method of diagnosing Cowden syndrome (CS) and Cowden-like Syndrome (CLS) is described. The method includes diagnosing CS and CLS in a subject by identifying a decrease in expression of the KILLIN gene, or by identifying hypermethylation of the KILLIN promoter region. Kits for diagnosing CS and CLS by identifying subjects having KILLIN promoter region hypermethylation and primers specific for a methylated KILLIN promoter region are also described. | 06-20-2013 |
20130172265 | Methods and Compositions for Inhibiting Tumor Cell Proliferation - The invention provides agents, compositions, pharmaceutical compositions and method for inhibiting tumor cell proliferation by inhibiting FoxM1B activity, expression, or nuclear localization in a tumor cell. | 07-04-2013 |
20130217634 | PEPTIDES ABLE TO INTERFERE WITH THE INHIBITING ACTIVITY OF MDM2/MDM4 HETERODIMER TOWARDS P53 AND USE THEREOF FOR CANCER TREATMENT - The present disclosure concerns peptides able to interfere and in particular impair the inhibiting activity of MDM2/MDM4 heterodimer towards p53 and maintain the association between MDM4 and p53 so to restore the p53 oncosuppressive function in cancer cells harboring wild type p53 protein, directing its function specifically towards an apoptotic outcome. | 08-22-2013 |
20130316959 | USE OF ENDOSTATIN PEPTIDES FOR THE TREATMENT OF FIBROSIS - C-terminal endostatin polypeptides are disclosed herein. Polynucleotides encoding these polypeptide, host cells transformed with the polynucleotides, and methods of using these polypeptides and polynucleotides are disclosed. Uses of these polypeptide, polynucleotides and expression vectors include the treatment of fibrosis in a subject. Thus, methods are provided for treating fibrosis, including fibrosis of the skin and/or the lung. | 11-28-2013 |
20140005117 | COMPOSITIONS AND METHODS FOR TREATING AIDS OR CANCER BY INHIBITING THE SECRETION OF MICROPARTICLES | 01-02-2014 |
20140121170 | COMPOSITIONS AND METHODS FOR TREATING AIDS OR CANCER BY INHIBITING THE SECRETION OF MICROPARTICLES - Novel peptides that inhibit the release of microparticles from cells are disclosed. The peptide contains at least one VGFPV motif at the N-terminal and has a length of 10-100 amino acids. Also disclosed is polynucleotide encoding the peptide, expression vectors carrying the polynucleotide, and methods for treating AIDS and tumors using the novel peptides. | 05-01-2014 |
20140135271 | Lamin A, An Activator of Longevity/Anti-Aging SIRT1 Protein - In one embodiment, the present invention provides methods of modulating the deacetylase activity of SIRT1 in one or more cell by modifying the binding affinity of lamin A to SIRT1 via one or more interaction modifying compound. In another embodiment, the present invention provides methods of screening SIRT1-activating/inhibiting compounds based on the interaction between lamin A and SIRT1 proteins and SIRT1-activating property of lamin A. In another embodiment, the present invention provides uses of SIRT1-activating compounds to treat patient(s) suffering from metabolic and/or aging-related degenerative diseases, and uses of SIRT1-inhibiting compounds to treat human malignancies. | 05-15-2014 |
20140187494 | INHIBITION OF INFLAMMATION USING ANTAGONISTS OF MUC1 - The invention provides for peptides from the MUC1 cytoplasmic domain and methods of use therefor. These peptides can inhibit MUC1 oligomerization, inhibit the interaction of MUC1 with NF-κB or a STAT, and block inflammatory response mediated by NF-κB or STAT signaling. | 07-03-2014 |
20140274907 | PYRROLOBENZODIAZEPINES - A compound with the formula (I), wherein: R | 09-18-2014 |
20140378388 | TREATMENT OF UTERINE LEIOMYOMATA - Embodiments herein provide a therapy for uterine leiomyomata (UL) in women using a fatty acid synthase (FAS) inhibitor. Additionally, an analysis method for evaluating the likelihood of women developing UL during their lifetime is provided. | 12-25-2014 |
20150051153 | Environmentally Sensitive Compositions - An environmentally sensitive membrane binding polypeptide, pH (low)-sensitive membrane peptide (pHLIP) has improved insertion kinetics balanced with solubility to selectively target acidic tissues. | 02-19-2015 |
20150367312 | METHOD FOR PRODUCING A MICROENCAPSULATE AND CORRESPONDING REACTIVE AMPHIPHILIC COMPOUND, MICROENCAPSULATE AND COMPOSITION - Method for producing a microencapsulate and corresponding reactive amphiphilic compound, microencapsulate and composition. Method for producing a polymeric, amphiphilic, highly functionalisable and versatile microencapsulate/nanoencapsulate, which comprises 2 stages: dispersing a first liquid phase in a second liquid phase forming an emulsion, in this way said first phase remains dispersed in said second phase, and polymerising a polymer that forms the wall of the microencapsulate. Between both phases an interphase is formed with a reactive amphiphilic compound, which is a prepolymer of the polymer. The amphiphilic compound has two more main functional groups that react in the subsequent polymerisation to produce the polymer. These two main functional groups are separated from each other by between 4 to 12 links. The amphiphilic compound has at least one hydrophilic or hydrophobic functional group in one chain which is sideways with respect to the chain that links both main functional groups. | 12-24-2015 |
20160067305 | Lamin A, An Activator of Longevity/Anti-Aging SIRT1 Protein - In one embodiment, the present invention provides methods of modulating the deacetylase activity of SIRT1 in one or more cell by modifying the binding affinity of lamin A to SIRT1 via one or more interaction modifying compound. In another embodiment, the present invention provides methods of screening SIRT1-activating/inhibiting compounds based on the interaction between lamin A and SIRT1 proteins and SIRT1-activating property of lamin A. In another embodiment, the present invention provides uses of SIRT1-activating compounds to treat patient(s) suffering from metabolic and/or aging-related degenerative diseases, and uses of SIRT1-inhibiting compounds to treat human malignancies. | 03-10-2016 |
20160250279 | Composition for Treating and Preventing Benign Prostatic Hyperplasia | 09-01-2016 |
20160375095 | METHOD OF TREATING OR PREVENTING BENIGN PROSTATIC HYPERPLASIA USING MODIFIED PORE-FORMING PROTEINS - The present invention provides a method of treating BPH using modified pore-forming proteins (MPPs). These MPPs are derived from naturally occurring cytotoxic proteins (nPPs) that kill cells by forming pores or channels in the cell membrane, resulting in cell death. The MPPs are generated by modification of the nPPs such that they are capable of being selectively activated at normal prostate cells. Such modification may include the addition of a prostate-specific protease cleavage site to the activation sequence, and/or the addition of a prostate-specific targeting domain to allow selective targeting of prostate cells. These MPPs are capable of selectively targeting and killing normal prostate cells in vivo. The MPPs may be used either alone or in combination with other therapies for the treatment of BPH. | 12-29-2016 |